Zacks Investment Research upgraded shares of Celsion (NASDAQ:CLSN) from a hold rating to a buy rating in a report issued on Tuesday morning, Zacks.com reports. They currently have $2.00 price target on the biotechnology company’s stock.
According to Zacks, “Celsion is dedicated to the development and commercialization of oncology drugs including tumor-targeting treatments using focused heat energy in combination with heat activated drug delivery systems. Celsion has research, license or commercialization agreements with leading institutions such as the National Institutes of Health, Duke University Medical Center, University of Hong Kong, North Shore Long Island Jewish Health System. “
A number of other research analysts have also commented on the company. Brookline Capital Management restated a buy rating on shares of Celsion in a research note on Thursday, July 25th. ValuEngine upgraded Celsion from a sell rating to a hold rating in a research note on Thursday, August 1st.
Shares of CLSN stock opened at $1.90 on Tuesday. Celsion has a 12 month low of $1.35 and a 12 month high of $3.10. The stock has a 50 day moving average of $1.76 and a 200-day moving average of $2.02. The company has a current ratio of 3.47, a quick ratio of 3.47 and a debt-to-equity ratio of 0.58.
Celsion (NASDAQ:CLSN) last issued its earnings results on Wednesday, August 14th. The biotechnology company reported ($0.29) EPS for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.04. The business had revenue of $0.13 million during the quarter, compared to analyst estimates of $0.13 million. Celsion had a negative return on equity of 53.40% and a negative net margin of 1,489.20%. As a group, sell-side analysts expect that Celsion will post -0.88 EPS for the current fiscal year.
An institutional investor recently raised its position in Celsion stock. BlackRock Inc. lifted its position in Celsion Co. (NASDAQ:CLSN) by 21.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 142,426 shares of the biotechnology company’s stock after purchasing an additional 25,548 shares during the quarter. BlackRock Inc. owned 0.76% of Celsion worth $202,000 at the end of the most recent reporting period. Institutional investors own 4.73% of the company’s stock.
Celsion Company Profile
Celsion Corporation, a development stage oncology drug company, focuses on the development and commercialization of directed chemotherapies, DNA-mediated immunotherapy, and RNA based therapies for the treatment of cancer. Its lead product candidate is ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trial for treating primary liver cancer.
Featured Article: The risks of owning bonds
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Celsion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion and related companies with MarketBeat.com's FREE daily email newsletter.